Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
for Type 2 Diabetes
17 locations incl. Birmingham
Sponsor: Biomea Fusion Inc.
Sex: All·Age: 18 - 70
Code: NCT07502508·Phase 2·Recruiting·Listed Mar 2026